Singapore Institute of Advanced Medicine Holdings Ltd. Announces Full Utilisation of Placement Proceeds

Key Highlights

• The company has fully utilised the net proceeds of S\$644,000 from its recent share placement exercise.
• All funds were allocated to general working capital, specifically for the payment of maintenance fees for medical equipment.
• The use of proceeds is in line with prior announcements and the intended purpose disclosed to investors.
• The company acknowledged an oversight in not immediately announcing the material utilisation of these proceeds.
• The placement exercise involved the issue of 19,748,000 new shares at a placement price of S\$0.035 per share, completed on 15 October 2025.
• No remaining balance of the placement proceeds as of the date of the announcement.

Details of the Placement and Use of Proceeds

Singapore Institute of Advanced Medicine Holdings Ltd. (SIAMH), together with its subsidiaries, completed a placement exercise on 15 October 2025, issuing a total of 19,748,000 new shares at S\$0.035 per share to certain subscribers. This exercise raised net proceeds of approximately S\$644,000.

On 16 January 2026, the company fully utilised the entire sum of the net proceeds for general working capital purposes. Specifically, the funds were used to pay maintenance fees for the Group’s medical equipment, which are critical for ongoing operations and service delivery.

No portion of the placement proceeds remains unutilised as at the date of the announcement.

Potentially Price-Sensitive Information

• Full Utilisation of Proceeds: The complete deployment of the S\$644,000 for maintenance fees indicates that SIAMH is actively investing in the upkeep of its medical equipment, which is essential for maintaining operational standards and supporting continued revenue generation.
• Disclosure Oversight: The company acknowledged that it failed to make an immediate announcement when the proceeds were materially utilised. While the funds were used in accordance with previously stated intentions, this lapse in prompt disclosure may raise questions about internal controls and corporate governance practices, potentially impacting investor confidence.
• Implications for Shareholders: Investors should note that the proceeds have not been used for expansion, acquisitions, or other growth initiatives, but rather for operational maintenance. While this supports business continuity, it does not directly contribute to new business growth or diversification.

Additional Background

• SIAMH was listed on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST) on 16 February 2024.
• The company’s initial public offering was sponsored by PrimePartners Corporate Finance Pte. Ltd.
• This announcement has been reviewed by the sponsor but not examined or approved by the SGX-ST, which assumes no responsibility for its contents.

Conclusion

The full utilisation of the placement proceeds for maintenance of medical equipment demonstrates SIAMH’s focus on maintaining operational reliability. However, the oversight in timely disclosure may be a point of concern for corporate governance. Investors should monitor future announcements for improvements in disclosure practices and any new developments regarding business expansion or strategic initiatives.

Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Investors should conduct their own research and consult professional advisors before making investment decisions. The information presented here is based on company disclosures as of 2 February 2026 and may be subject to change.

View SAM Holdings Historical chart here